Skip to content
Menu

Monte Rosa Therapeutics, Inc. GLUE

Full chart Compare
Set alert

Price alert · GLUE

All alert types
8.91 USD -0.16 (-1.76%)

Regular-session close

8.91 0.00 0.00%

After hours · Nov 19, 5:16 PM ET

8.76 Day range 9.28
8.76 52-week range 25.77
YTD
-43.18%
1 year
-36.99%

5D -1.29 (-12.34%)

99.501010.50TueWedThuFriMon9.16
Market cap
761.36M
Revenue (ttm)
28.73M
EPS (ttm)
-1.39
Shares out
85.31M
Forward P/E
-6.37
YTD return
-43.18%
1-year return
-36.99%
50-day average
15.55
Volume
1.11M
Avg volume
1.34M
Open
9.08
Previous close
9.07
Day's range
8.76 – 9.28
52-week range
8.76 – 25.77
Beta
1.50
Price target
28.50 (+219.9%)

Key statistics

200-day average
18.27
Enterprise value
418.46M
Price / sales
35.43
Price / book
2.09
Revenue growth
-61.30%
Free cash flow
-74.45M
Total cash
621.10M
Total debt
37.99M
Return on equity
-42.66%
Short % of float
22.94%

Fundamental scorecard

4 of 25 checks passed on GLUE’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
GLUE Revenue — quarterly 54.37M
GLUE Net income — quarterly 3.06M
GLUE EPS — quarterly 0.03

Earnings

GLUE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 2026-0.22694———
Aug 6, 2026Jun 30, 2026-0.38048-0.43-0.05-13.02%
May 7, 2026Mar 31, 2026-0.28-0.45-0.17-60.71%
Mar 17, 2026Dec 31, 2025-0.35153-0.54-0.19-53.61%
Nov 6, 2025Sep 30, 2025-0.36634-0.33+0.04+9.92%
Aug 7, 2025Jun 30, 2025-0.37683-0.15+0.23+60.19%

Upgrades / downgrades

GLUE analyst upgrades and downgrades
DateFirmActionFromTo
Sep 9, 2026WedbushreitOutperformOutperform
Aug 25, 2026GuggenheimreitBuyBuy
Aug 7, 2026JP MorganmainOverweightOverweight
Aug 7, 2026GuggenheimmainBuyBuy
Aug 7, 2026Wells FargomainOverweightOverweight
Aug 3, 2026WedbushmainOutperformOutperform

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on GLUE — it syncs with the Stock Master app.

Insider holders

GLUE insider holders
InsiderRelationLatest transactionDateShares held
BOWEN MATTHEWOfficerStock Award(Grant)Apr 5, 202625,904
CHAMPOUX JENNIFERChief Operating OfficerSaleJul 14, 202662,371
DUNN EDMUNDOfficerSaleMar 3, 202622,554
JANKU FILIPOfficerSaleJun 29, 202660,612
LEO CHANDRA P. MDDirectorPurchaseMar 23, 202510,000
MANNING ANTHONY MDirectorSaleJun 28, 20260

Institution ownership

GLUE institution ownership
Holder% heldSharesValueReported
Price (T.Rowe) Associates Inc10.39%8,861,171105.71MJun 29, 2026
NEA Management Company, LLC9.02%7,692,29891.77MJun 29, 2026
Blackrock Inc.8.02%6,843,08781.64MJun 29, 2026
TCG Crossover Management, LLC5.42%4,622,15155.14MJun 29, 2026
Vestal Point Capital, LP5.39%4,600,00054.88MJun 29, 2026
BVF Inc.5.23%4,460,88653.22MJun 29, 2026

Fund ownership

GLUE fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.99%2,550,82730.43MJun 29, 2026
T. Rowe Price New Horizons Fund, Inc.2.62%2,232,09126.63MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.62%2,231,48726.62MAug 30, 2026
iShares Trust-iShares Russell 2000 ETF2.23%1,899,25122.66MAug 30, 2026
T. Rowe Price Health Sciences Fund, Inc.2.14%1,823,21021.75MJun 29, 2026
T. ROWE PRICE QUANTITATIVE Mgmt Fd.S, INC.-T. Rowe Price Integrated U.1.61%1,375,63916.41MJun 29, 2026